Trial Profile

Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
25 Aug 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com